Blocking Fas-signaling in adipocytes and hepatocytes prevents obesity-associated inflammation, insulin resistance, and hepatosteatosis

•1. Obese mice exhibit increased Fas-signaling in adipocytes and liver.•2. Fas-signaling plays a pivotal role in obesity-associated consequences.•3. Systemic delivery of Fas-blocking peptide to adipose tissue and liver in obese mice.•4. The FBP treatment reduces apoptosis, inflammation, free fatty acids and triglycerides.•5. The FBP treatment improves liver steatosis and metabolic dysfunction in obese mice.